All In Biotech

Drug Trial Radar · NCT07417189

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

A Phase I/II, Open-Label Study of ABSK141 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients With KRAS G12D Mutant Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

401

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Dec 30, 2028

Study completion Jul 30, 2029

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.

Conditions

  • Solid Tumors, Adult

Interventions

  • ABSK141-400mgDrug

    In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 400mg administration. Thereafter, patients will continuously receive ABSK141 400mg once daily (QD).

  • ABSK141-Recommended Dose for Expansion (RDE)Drug

    In the expansion part# patients will orally receive ABSK141 at the recommended dose for expansion (RDE).patients will continuously receive ABSK141 Recommended Dose for Expansion (RDE) once daily (QD).

  • ABSK141-800mgDrug

    In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 800mg administration. Thereafter, patients will continuously receive ABSK141 800mg once daily (QD).

  • ABSK141-1200mgDrug

    In the escalation part#patients will first orally receive a single dose of ABSK141 on D-3, followed by a three-day run-in period to assess the PK profile of singledose ABSK141 1200mg administration. Thereafter, patients will continuously receive ABSK141 1200mg once daily (QD).

  • ABSK141-Recommended Phase 2 dose (RP2D)Drug

    Phase II #patients will orally receive ABSK141 at the Recommended Phase 2 Dose (RP2D).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTsTime frame: from Run-in to Day28
  2. Incidence and severity of AEsTime frame: from the time that the patient provides informed consent through and including 30 days after the last administration of ABSK141.
  3. Incidence and severity of SAEsTime frame: from the time that the patient provides informed consent through and including 30 days after the last administration of ABSK141.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.